In the phase III OAK study, only 11.0% of ICI-treated patients with NSCLC showed a CRP flare-response, whereas our previous data suggest a more frequent occurrence [eg, 26.9% of our immune monitoring of immune therapy (IMIT) NSCLC cohort (5)] of the CRP flare-response phenomenon. Here, CRP is linked to non-small cell lung carcinoma.